Biotechnology firm, Unity Biotechnology, Inc., has established itself as a crucial player in the fight against aging-related diseases. Through its robust research and development program, Unity Biotechnology is developing revolutionary therapeutics that could potentially slow, halt, or even reverse the effects of aging. The company's lead product, UBX1325, is currently in phase II clinical trial for the treatment of age-related diseases of the eye, such as diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The firm is also working on other promising treatments, such as UBX1967 for ophthalmologic diseases, UBX2050 for age-related eye diseases, and UBX2089 – a hormone drug candidate for multiple neurology indications. Originally founded as Forge, Inc., Unity Biotechnology shifted its focus and rebranded in January 2015. The California-based company has been at the forefront of the biotech industry since its incorporation in 2009, headquartered in South San Francisco.